A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | MicrobiomeTrials← Back to trialsNCT07195682
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-01-15Est. Completion: 2030-05-03
Enrollment target: 125 participants Locations- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- START San Antonio, San Antonio, Texas, United States
- Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- Gustave Roussy, Villejuif, Val-de-Marne, France
- Hospital Universitario Reina Sofia, Córdoba, Andalusia, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain
Other microbiome trials you might be interested in
Liver Cancer (Primary and Metastatic)Lung Cancer (Diagnosis)Bone Cancer MetastaticBone Cancer TumorKidney TumorsRenal CancerHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)Musculoskeletal CancersMusculoskeletal TumorsBone TumorsLung Tumors
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating ho…
Lyon, FranceEst. completion Dec 31, 2030
First line of the email MUST contain NCT # and Site #.
Phase 1
Recruiting
Head and Neck TumorsKidney CancersSmall Cell Lung CancersPheochromocytoma/ParagangliomasGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive
Background:
Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumor…
Bethesda, United StatesEst. completion Jan 1, 2029
Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8Esophageal CarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaLocally Advanced Urothelial CarcinomaLung Non-Small Cell CarcinomaMalignant Solid NeoplasmMetastatic Colorectal CarcinomaMetastatic Cutaneous MelanomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Urothelial CarcinomaRecurrent Esophageal Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRenal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Cutaneous MelanomaUnresectable Esophageal Squamous Cell CarcinomaUrothelial CarcinomaUnresectable Urothelial Carcinoma
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setti…
Jacksonville, United StatesEst. completion Dec 31, 2026